Myasthenia gravis (MG) is an autoimmune disease caused by the dysfunction of nerve-muscle junction transmission. The clinical manifestations are mainly partial or systemic skeletal muscle weakness and fatigue. The prevalence rate is (77~150)/1 million, and the annual incidence rate is (4~11)/1 million. Recently, research from Zhao Chongbo and Luo Sushan’s team in Huashan Hospital of Fudan University found out that low-dose rituximab (RTX) is effective in the treatment of patients with acetylcholine receptor (AChR) positive refractory myasthenia gravis. Meanwhile, RTX can reduce the level of serum exosome miR-150. The results suggest that exosome miR-150 is a potential biomarker for myasthenia gravis disease.
![Nanocoulter I [drug carrier quality control, nano particle detection] - to meet your scientific research needs](https://pmo54fe17-pic15.websiteonline.cn/upload/7eem.jpg)
